Podcast

From Medic to Multimillion Dollar Exit

Catch the Full Episode

Most conversations about scaling focus on speed. The people who’ve actually built and exited healthcare businesses focus on timing.

For the second episode of The End Podcast, Biorce CEO Pedro Coelho sits down with Thomas Dobmeyer (Advisor at ekwithtree), a medic by training and an exited healthcare founder,  who has built, scaled, and exited a real healthcare business in a highly regulated environment.

They talk about what disciplined growth actually looks like when regulation, trust, and long-term value matter more than momentum.

They discuss:

• When scaling creates value — and when it destroys it

• Why scaling too early is one of the most expensive mistakes founders make

• How leadership changes after an exit

• How trust, credibility, and execution compound over time

This is not startup theory. It's a lived experience from someone who’s done it —end to end — in healthcare.

Most conversations about scaling focus on speed. The people who’ve actually built and exited healthcare businesses focus on timing.

For the second episode of The End Podcast, Biorce CEO Pedro Coelho sits down with Thomas Dobmeyer (Advisor at ekwithtree), a medic by training and an exited healthcare founder,  who has built, scaled, and exited a real healthcare business in a highly regulated environment.

They talk about what disciplined growth actually looks like when regulation, trust, and long-term value matter more than momentum.

They discuss:

• When scaling creates value — and when it destroys it

• Why scaling too early is one of the most expensive mistakes founders make

• How leadership changes after an exit

• How trust, credibility, and execution compound over time

This is not startup theory. It's a lived experience from someone who’s done it —end to end — in healthcare.

Want to become a podcast guest?

Reach out

Ready to accelerate your
next clinical trial?

Reach out

Ready to accelerate your
next clinical trial?

Reach out

Get the inside track on clinical trial innovation Insights that pharma leaders actually read. No fluff.

@2026 Biorce | All Rights Reserved

Partners with

Get the inside track on clinical trial innovation Insights that pharma leaders actually read. No fluff.

@2026 Biorce | All Rights Reserved

Partners with

Get the inside track on clinical trial innovation Insights that pharma leaders actually read. No fluff.

Partners with

@2026 Biorce | All Rights Reserved